Measured Wealth Private Client Group LLC Lowers Stock Holdings in Cencora, Inc. (NYSE:COR)

Measured Wealth Private Client Group LLC trimmed its stake in Cencora, Inc. (NYSE:COR) by 40.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,934 shares of the company’s stock after selling 1,298 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Cencora were worth $435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in COR. New Millennium Group LLC purchased a new stake in Cencora in the 2nd quarter valued at about $26,000. TCTC Holdings LLC purchased a new stake in Cencora in the 1st quarter valued at about $29,000. TFO Wealth Partners LLC purchased a new stake in Cencora in the 1st quarter valued at about $30,000. MFA Wealth Advisors LLC purchased a new stake in Cencora in the 2nd quarter valued at about $30,000. Finally, Concord Wealth Partners purchased a new stake in Cencora in the 3rd quarter valued at about $30,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on COR. Evercore ISI lowered their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Leerink Partners lowered their price target on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Wells Fargo & Company upped their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Finally, Robert W. Baird lowered their price target on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 15.80% of the stock is currently owned by company insiders.

Cencora Trading Down 1.5 %

NYSE:COR opened at $226.15 on Thursday. Cencora, Inc. has a 52 week low of $182.75 and a 52 week high of $247.66. The firm has a 50 day moving average of $231.71 and a 200 day moving average of $230.72. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The stock has a market capitalization of $44.56 billion, a price-to-earnings ratio of 24.92, a PEG ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, beating analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. During the same quarter in the prior year, the company posted $2.92 earnings per share. Cencora’s revenue for the quarter was up 10.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.